

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Laekna, Inc.

來凱醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2105)

VOLUNTARY ANNOUNCEMENT

IND-ENABLING STUDY INITIATED FOR LAE123 FOR THE TREATMENT OF SEVERE DISEASES

This announcement is made by Laekna, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board (the “**Board**”) of directors of the Company (the “**Directors**”) is pleased to announce that the Group has advanced LAE123 to pre-clinical candidate declaration and has initiated an IND-enabling study for LAE123 for the treatment of severe diseases. LAE123 is an ActRIIA/IIB dual antagonistic monoclonal antibody that can potently block the interaction between ActRIIA/IIB and their ligands, including Myostatin, Activins and Growth/differentiation factors. LAE123 is a strong ActRIIA and ActRIIB blocker which has shown superior potency in cell-based reporter gene assays (RGA), excellent pharmacokinetics and efficacy in animal studies.

Dysregulation of ActRII signaling has been implicated in many diseases, such as obesity, sarcopenia, and other severe diseases. We will explore LAE123 as new treatments in life threatening severe diseases such as pulmonary arterial hypertension and spinal muscular atrophy.

About LAE123

LAE123 is an internally discovered monoclonal antibody that dually inhibits ActRIIA/IIB signaling induced by their ligands, including Myostatin, Activins (such as Activin A, Activin B, Activin AB, Activin C, and Activin E), and Growth/differentiation factors (GDFs, such as GDF3 and GDF11). Dysregulation of ActRII signaling has been implicated in many diseases, such as obesity, sarcopenia, and other severe diseases.

RISK WARNING

LAE123 MAY NOT ULTIMATELY BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By Order of the Board
Laekna, Inc.
Dr. LU Chris Xiangyang
Chairman

Hong Kong, November 28, 2024

As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.